List of Dymista drug patents

Dymista is owned by Mylan Speciality Lp.

Dymista contains Azelastine Hydrochloride; Fluticasone Propionate.

Dymista has a total of 7 drug patents out of which 0 drug patents have expired.

Dymista was authorised for market use on 01 May, 2012.

Dymista is available in spray, metered;nasal dosage forms.

Dymista can be used as treatment of seasonal allergic rhinitis; treatment of allergic rhinitis, including seasonal allergic rhinitis; allergic rhinitis; treatment of symptoms of seasonal allergic rhinitis; relief of symptoms associated with seasonal allergic rhinitis, treatment of seasonal allergic rhinitis.

The generics of Dymista are possible to be released after 24 August, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(4 months from now)

US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Jun, 2023

(4 months from now)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2023

(6 months from now)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration
Dec, 2023

(10 months from now)

US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2024

(1 year, 1 month from now)

US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2026

(3 years from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2026

(3 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: Treatment of seasonal allergic rhinitis; Treatment of allergic rhinitis, including seasonal allergic rhinitis; Allergic rhinitis; Treatment of symptoms of seasonal allergic rhinitis; Relief of symptoms associated with seasonal allergic rhinitis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of DYMISTA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic